Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

Abstract Introduction Long-term safety data are critical for evaluating therapies for psoriasis. Ixekizumab has demonstrated efficacy and is well tolerated for the treatment of moderate-to-severe plaque psoriasis. We examined the safety and tolerability of up to 5 years of ixekizumab therapy in pati...

Full description

Bibliographic Details
Main Authors: April Armstrong, Carle Paul, Luis Puig, Wolf Henning Boehncke, Michael Freeman, Hideshi Torii, Kim Papp, Christopher E. M. Griffiths, Andrew Blauvelt, Kristian Reich, Melinda Gooderham, Tadashi Terui, Lisa Renda, Noah Agada, Wen Xu, Gaia Gallo, Mark G. Lebwohl
Format: Article
Language:English
Published: Adis, Springer Healthcare 2019-11-01
Series:Dermatology and Therapy
Subjects:
Adverse events
Etanercept
IL-17
Integrated analysis
Ixekizumab
Safety
Online Access:http://link.springer.com/article/10.1007/s13555-019-00340-3

Internet

http://link.springer.com/article/10.1007/s13555-019-00340-3

Similar Items